What works in Dactylitis? Literature review suggests ustekinumab, ixekizumab, adalimumab, and apremilast are efficient. Secukinumab, clazakizumab, abatacept, and tofacitinib were promising. Brodalumab was ineffective https://t.co/SLPcjBaNAv